Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 500660 | NSE Symbol : GLAXO | ISIN : INE159A01016 | Industry : Pharmaceuticals - Multinational |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-Jan-2025	14-Feb-2025	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve Un Audited financial results for quarter and nine months ended 31st December 2024 Further to letter dated 15th January 2025, relating to intimation of Board Meeting scheduled to be held on Monday, 10th February 2025 the Board meeting is rescheduled on Friday, 14th February 2025 inter-alia, to approve and take on record the Un-audited financial results for the third quarter & nine months ended 31st December 2024. As per attachment (As per BSE Announcement Dated on 20/01/2025) outcome attachment (As Per BSE Announcement Dated on 14.02.2025)
24-Oct-2024	29-Oct-2024	Interim Dividend	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve Unaudited Financial Results for quarter & half year ended 30th September 2024 and to consider the declaration of interim dividend (if any) Outcome of Meeting The Board has recommended Special Interim dividend of Rs. 12/- (120%) per equity share on face value of Rs.10 each of the Company. (As Per BSE Announcement Dated on 29.10.2024)
17-Jul-2024	02-Aug-2024	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2024 inter alia to consider and approve Un-Audited Financial Results for the first quarter ended 30th June 2024 Outcome of meeting (As Per BSE Announcement dated on 02.08.2024)
19-Apr-2024	17-May-2024	Accounts	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve Pursuant to clause 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations 2015 (LODR) this is to inform you that a meeting of the Board of Directors of our Company will be held on Friday 17th May 2024 inter-alia to consider amongst other things approval of audited financial results (Standalone & Consolidated) for the quarter / year ended 31st March 2024 and to recommend dividend if any on the equity shares of the Company. Audited Results & Final Dividend (As per BSE Bulletin dated on 19/04/2024) Outcome of Board Meeting (As per BSE Announcement Dated on 17/05/2024)
26-Dec-2023	12-Feb-2024	Quarterly Results	Closure of Trading window GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and approve Un-Audited Financial Results for the third quarter and nine months ended 31st December 2023 (As Per BSE Announcement Dated on 04.01.2024) outcome of Board Meeting Unaudited Financial Results for third quarter and nine months ended 31st December 2023 (As Per BSE Announcement Dated on 12/02/2024)
04-Oct-2023	09-Nov-2023	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Un-Audited Financial Results for the second quarter and half year ended 30th September 2023 Unaudited financials Results for second quarter & half year ended 30th September 2023 Unaudited (Standalone and Consolidated) financial results for the second quarter & half year ended 30th September 2023 (As Per BSE Announcement Dated on 09/11/2023)
26-Jun-2023	26-Jul-2023	Quarterly Results	Closure of Trading Window We wish to inform you that the in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Company's shares is closed from Saturday, 1 st July 2023 and shall reopen on Saturday, 29 th July 2023 i.e. after the approval & declaration of Unaudited financial results for first quarter ended 30 th June 2023 by the Board of Directors at its meeting scheduled to be held on Wednesday, 26 th July 2023. Unaudited (Standalone and Consolidated) financial results for the first quarter ended 30th June 2023 Unaudited Results for quarter ended 30th June 2023 (As Per BSE Announcement Dated on 26.07.2023)
03-May-2023	17-May-2023	Accounts	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2023 inter alia to consider and approve Audited Financial Results (Standalone & Consolidated) for the year ended 31st March 2023 and to recommend dividend if any on the equity shares of the Company. Outcome of Board Meeting Audited Results for year ended March 2023 Dividend for year ended March 2023 (As per BSE Announcement Dated on 17/05/2023)
11-Jan-2023	07-Feb-2023	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 inter alia to consider and approve Un- Audited Financial Results for the third quarter & nine months ended 31st December 2022 Unaudited (Standalone and Consolidated) financial results for the third quarter & nine months 31st December 2022 (As Per BSE Announcement Dated on 07.02.2023)
31-Oct-2022	11-Nov-2022	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Un- Audited Financial Results for the second quarter & half year ended 30th September 2022 Outcome of Meeting (As Per BSE Announcement Dated on 17.10.2022) Outcome of Board Meeting (As Per BSE Announcement dated on 11.11.2022) Advertisement relating Results (As per BSE Announcement Dated on 15/11/2022)
28-Jun-2022	25-Jul-2022	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2022 inter alia to consider and approve Un- Audited Financial Results for the first quarter ended 30th June 2022 Unaudited (Standalone and Consolidated) financial results for the first quarter ended 30th June 2022 Change in Directorate (As per BSE Announcement Dated on 25/07/2022)
02-May-2022	16-May-2022	Accounts	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2022 inter alia to consider and approve Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations 2015 (LODR) this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday 16th May 2022 inter-alia to consider amongst other things approval of audited financial results (Standalone & Consolidated) for the quarter / year ended 31 st March 2022 and to recommend dividend if any on the equity shares of the Company. Board approved: 1. Dividend The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022. (As Per BSE Bulletin Dated on 16.05.2022) outcome of meeting (As per BSE Announcement Dated on 16/5/2022) The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022. (As per BSE Announcement Dated on 10/06/2022)
28-Dec-2021	07-Feb-2022	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2022 inter alia to consider and approve Un- Audited Financial Results for the third quarter& nine months ended 31st December 2021 Unaudited (Standalone and Consolidated) financial results for the third quarter and nine months ended 31st December 2021 Change in Directorate (As Per BSE Announcement dated on 07.02.2022)
27-Sep-2021	29-Oct-2021	Quarterly Results	Quarterly Results Outcome of the Board Meeting (As Per BSE Announcement dated on 29.10.2021)
06-Jul-2021	26-Jul-2021	Quarterly Results	GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2021 ,inter alia, to consider and approve Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations,2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday, 25th July 2021, inter-alia, to consider approval of Un-audited financial results for the first quarter ended 30th June 2021 . Pursuant to Clause 33 read with Clause 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, please find enclosed herewith the Un-Audited Standalone and Consolidated Financial Results and Limited Review Report for the quarter ended 30th June 2021. As per attachment (As Per BSE Announcement dated on 26.07.2021)

1 2

LOGIN HERE

Glaxosmithkline Pharmaceuticals Ltd

Board Meeting